(Q34983475)

5 August 2017

1 reference

title

Attention-deficit-hyperactivity disorder: an update (English)

1 reference

attention deficit hyperactivity disorder

5 August 2017

main subject

0 references

author name string

Julie A Dopheide

series ordinal

1

1 reference

5 August 2017

Steven R Pliszka

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

5 August 2017

1 reference

5 August 2017

volume

29

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

656-679

1 reference

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Attention-Deficit/Hyperactivity Disorder in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

3-Year Follow-up of the NIMH MTA Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

A review of the economic burden of ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Prospective effects of attention-deficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Attention deficit hyperactivity disorder and substance use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Molecular genetics of attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Genetics of attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Polymorphisms of the dopamine D4 receptor, clinical outcome, and cortical structure in attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Attention-deficit hyperactivity symptomatology after traumatic brain injury: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Can inattention/overactivity be an institutional deprivation syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Role of dopamine transporter genotype and maternal prenatal smoking in childhood hyperactive-impulsive, inattentive, and oppositional behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Gene-environment interactions in the development of combined type ADHD: evidence for a synapse-based model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Prenatal Smoking Exposure and Dopaminergic Genotypes Interact to Cause a Severe ADHD Subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Interacting effects of the dopamine transporter gene and psychosocial adversity on attention-deficit/hyperactivity disorder symptoms among 15-year-olds from a high-risk community sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

The neural correlates of attention deficit hyperactivity disorder: an ALE meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Characterizing cognition in ADHD: beyond executive dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

A meta-analytic review of stopping performance in attention-deficit/hyperactivity disorder: deficient inhibitory motor control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Causal Heterogeneity in Attention-Deficit/Hyperactivity Disorder: Do We Need Neuropsychologically Impaired Subtypes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Neuropsychological functioning in stimulant-naive boys with hyperkinetic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Varieties of attention-deficit/hyperactivity disorder-related intra-individual variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Volumetric MRI differences in treatment-naïve vs chronically treated children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

The ecological validity of delay aversion and response inhibition as measures of impulsivity in AD/HD: a supplement to the NIMH multimodal treatment study of AD/HD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Psychological heterogeneity in AD/HD--a dual pathway model of behaviour and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Development of "hot" executive function: the children's gambling task.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Executive and motivational processes in adolescents with Attention-Deficit-Hyperactivity Disorder (ADHD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Ventral striatal hyporesponsiveness during reward anticipation in attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Hippocampus and amygdala morphology in attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Motor timing deficits in community and clinical boys with hyperactive behavior: the effect of methylphenidate on motor timing

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Time perception: modality and duration effects in attention-deficit/hyperactivity disorder (ADHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Neural and behavioral correlates of expectancy violations in attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

The neural bases of momentary lapses in attention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Cingulate-precuneus interactions: a new locus of dysfunction in adult attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Converging evidence for a fronto-basal-ganglia network for inhibitory control of action and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

ADHD symptoms and subtypes: relationship between childhood and adolescent symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Ten-year review of rating scales. V: scales assessing attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Parent versus teacher ratings of attention-deficit/hyperactivity disorder symptoms in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Pharmacological management of attention-deficit hyperactivity disorder in adolescents: special considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Safety and tolerability of methylphenidate in preschool children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Comorbidity moderates response to methylphenidate in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Pharmacological management of treatment-induced insomnia in ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Stimulants and sudden death: what is a physician to do?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Long-term effects of extended-release mixed amphetamine salts treatment of attention- deficit/hyperactivity disorder on growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

An overview of psychotropic drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Steady-state pharmacokinetics of bupropion SR in juvenile patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Complementary and alternative medical therapies for attention-deficit/hyperactivity disorder and autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Effects of iron supplementation on attention deficit hyperactivity disorder in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Pediatric bipolar disorder: emerging diagnostic and treatment approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Recognizing and treating depression in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Nature of anxiety comorbid with attention deficit hyperactivity disorder in children from a pediatric primary care setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Differential stimulant response on attention in children with comorbid anxiety and oppositional defiant disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Treatment of ADHD in children with tics: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

Delinquent Behavior and Emerging Substance Use in the MTA at 36 Months: Prevalence, Course, and Treatment Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.656

21 January 2018

Identifiers

DOI

10.1592/PHCO.29.6.656

1 reference

5 August 2017

1 reference